Drug-Target Association Kinetics in Drug Discovery

被引:53
作者
IJzerman, Adriaan P. [1 ]
Guo, Dong [2 ]
机构
[1] Leiden Univ, LACDR, Div Drug Discovery & Safety, POB 9502, NL-2300 RA Leiden, Netherlands
[2] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
PROTEIN-COUPLED RECEPTOR; BINDING-KINETICS; RESIDENCE TIME; IN-VIVO; LIGAND-BINDING; LONG; DISSOCIATION; MECHANISM; EFFICACY; PHARMACOLOGY;
D O I
10.1016/j.tibs.2019.04.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The important role of ligand-receptor binding kinetics in drug design and discovery is increasingly recognized by the drug research community. Over the past decade, accumulating evidence has shown that optimizing the ligand's dissociation rate constant can lead to desirable duration of in vivo target occupancy and, hence, improved pharmacodynamic properties. However, the association rate constant as a pharmacological principle remains less investigated, whereas it can play an equally important role in the selection of drug candidates. This review provides a compilation and discussion of otherwise scarce and dispersed information on this topic, bringing to light the importance of drug -target association in kinetics-directed drug design and discovery.
引用
收藏
页码:861 / 871
页数:11
相关论文
共 88 条
[1]   APPLICATION OF THE THEORY OF DIFFUSION-CONTROLLED REACTIONS TO ENZYME KINETICS [J].
ALBERTY, RA ;
HAMMES, GG .
JOURNAL OF PHYSICAL CHEMISTRY, 1958, 62 (02) :154-159
[2]   Electrostatic rate enhancement and transient complex of protein-protein association [J].
Alsallaq, Ramzi ;
Zhou, Huan-Xiang .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2008, 71 (01) :320-335
[3]   Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor [J].
Anthes, JC ;
Gilchrest, H ;
Richard, C ;
Eckel, S ;
Hesk, D ;
West, RE ;
Williams, SM ;
Greenfeder, S ;
Billah, M ;
Kreutner, W ;
Egan, RW .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 449 (03) :229-237
[4]  
Alonso JA, 2014, BIOORG MED CHEM LETT, V24, P5118, DOI 10.1016/j.bmcl.2014.09.005
[5]   Phase II failures: 2008-2010 [J].
Arrowsmith, John .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1
[6]   Indacaterol, a novel inhaled β2-agonist, provides sustained 24-h bronchodilation in asthma [J].
Beeh, K. M. ;
Derom, E. ;
Kanniess, F. ;
Cameron, R. ;
Higgins, M. ;
van As, A. .
EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :871-878
[7]   The Short, the Long, and the "Ultra-long": Why Duration of Bronchodilator Action Matters in Chronic Obstructive Pulmonary Disease [J].
Beeh, Kai M. ;
Beier, Jutta .
ADVANCES IN THERAPY, 2010, 27 (03) :150-159
[8]   Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD:: A 28-day randomised, placebo controlled clinical trial [J].
Beier, Jutta ;
Chanez, Pascal ;
Martinot, Jean-Benoit ;
Schreurs, A. J. M. ;
Tkacova, Ruzena ;
Bao, Weibin ;
Jack, Damon ;
Higgins, Mark .
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) :740-749
[9]   Entry from the Lipid Bilayer: A Possible Pathway for Inhibition of a Peptide G Protein-Coupled Receptor by a Lipophilic Small Molecule [J].
Bokoch, Michael P. ;
Jo, Hyunilo ;
Valcourt, James R. ;
Srinivasan, Yoga ;
Pan, Albert C. ;
Capponi, Sara ;
Grabe, Michael ;
Dror, Ron O. ;
Shaw, David E. ;
DeGrado, William F. ;
Coughlin, Shaun R. .
BIOCHEMISTRY, 2018, 57 (39) :5748-5758
[10]   Patient adherence in COPD [J].
Bourbeau, J. ;
Bartlett, S. J. .
THORAX, 2008, 63 (09) :831-838